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Abstract: Recurrent tonsillitis is described as when an individual suffers from several attacks 
of tonsillitis per year. Chronic and recurrent tonsillitis both cause repeated occurrences of 
inflamed tonsils which have a significant impact on a patient’s quality of life. Numerous 
children suffer from recurrent tonsillitis and sore throats, and these illnesses become part of 
their life. Antimicrobials can provide temporary relief, but in many cases, tonsillitis recurs. 
The cause of such recurrent infections have been identified as microorganisms which often 
create biofilms and a repository of infection in the wet and warm folds of the tonsils. This 
review discusses different treatment modalities, their advantages and disadvantages, and new 
treatment options focusing on biofilms. All treatment options should be selected based on 
evidence and individual need.
Keywords: chronic, recurrent tonsillitis, inflammation, tonsillectomy
Tonsillitis
Tonsillitis is an inflammation of the pharyngeal tonsils. The inflammation may affect 
other areas of the back of the throat, including the adenoids and the lingual tonsils. 
Acute tonsillitis is an infection of the tonsils triggered by one of the several types of 
bacteria or viruses, and peritonsillar abscesses can also occur. Chronic tonsillitis is a 
tenacious infection of the tonsils which may result in tonsil stones. Recurrent tonsil-
litis ensues when an individual suffers from several incidents of tonsillitis per year. 
Both chronic and recurrent tonsillitis involve repeated occurrences of inflamed tonsils 
which can impact severely on a patient’s quality of life.1,2 Children very often suffer 
from tonsillitis, although it is seldom observed below the age of 2 years. Tonsillitis 
due to Streptococcus bacteria classically happens in children aged between 5 and 15 
years, while viral tonsillitis is more prevalent in younger children.3 Multiple studies 
report that the average prevalence of carrier status of school children for group A 
Streptococcus is 15.9%.4,5
Epidemiology of tonsillitis
Numerous children so often suffer from recurrent tonsillitis and sore throats that these 
illnesses become part of their life. For example, one study indicates that ~30% of peri-
tonsillar abscesses require a tonsillectomy,6 and another indicates that recurrent tonsillitis 
is reported in 11.7% and 12.1% of Norwegian and Turkish children, respectively.7 Many 
of these patients are prescribed antimicrobials which typically provide temporary relief, 
but then the tonsillitis recurs.8 Scientists working at  Washington University School of 
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Medicine identified that recurrent infections are exacerbated 
by the creation of biofilms by microorganisms in the wet and 
warm folds of the tonsils which act as a repository of infec-
tion.9 A study utilizing an innovative imagining technique in 
single sections of human mucosal tissue reports the presence 
of biofilms in 70.8% of chronic tonsillitis patients.10 Another 
study revealed that biofilms were recognized on the surface 
epithelium of tonsils and adenoids in many of the patients 
who were waiting for adenotonsillectomy due to chronic 
tonsillitis and adenoiditis.11 Such biofilms are also observed in 
other otorhinolaryngology-related infections such as chronic 
rhinosinusitis and chronic otitis media with effusion.12,13
A brief overview of biofilms
Biofilms are systematized communities of microorganisms 
embedded in a hydrated matrix of extracellular polymeric sub-
stances (EPSs) causing diverse persistent infections, includ-
ing dental plaques, cystic fibrosis, urinary tract infections, 
osteomyelitis, and ear infections.9,14,15 Biofilm formation is a 
prehistoric prokaryotic strategy of a microorganism to exist 
and grow in antagonistic settings through building innovative 
communities involving several processes.16–19 The Dutch scien-
tist (commonly known as the Father of Microbiology) Antonie 
van Leeuwenhoek used his primitive but effective microscope 
to observe biofilms as early as 1674 and described aggregates 
of animalcules scraped from human tooth surfaces.20,21 The 
English phrase “survival of the fittest” arose from Darwinian 
evolutionary theory and describes one of the mechanisms of 
natural selection.22,23 Bacterial biofilm formation is a form of 
“survival of the fittest” under adverse conditions including 
chemical or antimicrobial treatment.24,25 The formation of 
biofilms by bacteria has three potential advantages: 1) “protec-
tion from harmful conditions in the host”, 2) “sequestration 
to a nutrient-rich area”, and 3) “utilization of cooperative 
benefits”.26 Microbial biofilms were identified as a major 
cause of many human infections, and present in more than 
65%–80% of all human bacterial infections.14,27–30 They pose 
“a serious problem for public health because of the increased 
resistance of biofilm-associated organisms to antimicrobial 
agents and the potential for these organisms to cause infec-
tions in patients with indwelling medical devices”.31 Biofilm 
formation is generally considered to arise in four core stages: 
1) attachment of bacteria to a surface, 2) microcolony forma-
tion, 3) biofilm maturation, and 4) detachment (also called 
dispersal) of bacteria which may then colonize new areas.32 
Other research studies reports that the process of biofilm for-
mation involves five stages:33–35 1) Microbial cells attach to 
surfaces reversibly.36 2) Microbial cells then attach to surfaces 
irreversibly.37 3) Cells get adsorbed on surfaces and grow into 
microcolonies; their physical dimensions are tens or hundreds 
of microns in diameter.38 4) The microbial fraternity grows into 
a three-dimensional configuration and settles down as a biofilm 
as cells replicate and the EPSs accumulate.39 5) Bacterial cells 
detach from biofilm and disperse into the bulk fluid, where they 
act as free-swimming bacteria and form new biofilms.16,17 This 
process of biofilm formation is depicted in Figures 1 and 2.
Distinct features of biofilm bacteria
Bacteria found inside biofilms have distinct features differ-
ent from those of free-swimming (planktonic) bacteria of 
Figure 1 Four different stages of biofilm development.
Note: Islam MS, Richards JP, Ojha AK. Targeting drug tolerance in mycobacteria: a perspective from mycobacterial biofilms. Expert Rev Anti Infect Ther. 2012;10(9):1055–1066, 
Taylor & Francis Ltd, http://www.tandfonline.com reprinted by permission of the publisher.150
Plankton
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the same classes and possess a very high level of resistance 
to commonly used antimicrobial remedies, biocides and 
 antiseptics, and the host immune response.40–42 Older, mature, 
and impenetrable biofilms are consistently more resistant to 
antimicrobials than younger, less dense biofilms.42 Bacte-
rial cells residing in the outermost parts of the biofilm are 
more vulnerable to the host’s defenses and antimicrobials, 
although these microorganisms possess numerous defensive 
mechanisms. The biofilm is formed of various microbial 
communities that create a complex three-dimensional 
physical barrier which hinders the diffusional penetration of 
antimicrobials.17,43,44 The metabolic activity of the bacteria 
residing in the exterior layer of biofilm alters the local pH to 
be more acidic and creates anoxic zones that help to degrade 
antimicrobials.45–48 The biofilm also creates nutrient-depleted 
areas which act on microbes to put them into a stationary or 
dormant phase, which may also contribute toward antibiotic 
resistance.49,50 The extracellular matrix of the biofilm secretes 
polymers that bind and deactivate antimicrobials, forming an 
antibiotic “sink”.51 These properties of biofilms (inadequate 
diffusion of nutrients, restricted antimicrobial transmission, 
and the alteration of the environment to produce a more hos-
tile environment) combine to produce a widespread resistance 
and tolerance to antimicrobials.16,43–56 In addition, microbes 
entrenched in a biofilm can exist even in the presence of high 
concentrations of bactericidal antimicrobials, although they 
are abundantly sensitive to those antimicrobials in culture 
plates under planktonic conditions.57 This complex phe-
nomenon is known as the “recalcitrance of biofilm bacteria 
toward antibiotics”,58 and microorganisms found in biofilms 
can be up to 500–1,000 times more tolerant to  antibacterial 
compounds than their planktonic counterparts.59–62 Addition-
ally, many studies report that as soon as a biofilm is rooted 
and fixed, microbes develop resistance to several categories 
of physicochemical aggression, including ultraviolet light, 
heavy metals, low pH, changes in hydration or salinity, and 
phagocytosis.63–67
Recurrent tonsillitis and 
tonsillectomy
Chronic tonsillitis affecting both children and adults is 
a serious health problem,68,69 and while the definition of 
severe recurrent tonsillitis varies, severity is described as 
five or more episodes of true tonsillitis a year, symptoms for 
at least a year, and episodes that are disabling and prevent 
normal functioning.70,71 In one study, the lifetime preva-
lence of recurrent tonsillitis is described as 11.7% (95% CI, 
11.0%–12.3%) with a significant preponderance of females.7 
Recurrent tonsillitis is typically treated by either surgery or, 
when the patient does not meet tonsillectomy benchmarks or 
there are surgical or medical contraindications, by medical 
antimicrobial intervention.72,73
While tonsillectomy (surgical removal of the tonsils, 
with or without adenoidectomy) as a treatment modality has 
been practiced for over 100 years for children, much contro-
versy exists around its value. As, for example, in 1951, the 
British Medical Journal reported that “it is better to delay 
a decision than to hurry it, and above all to avoid operating 
Figure 2 Five stages of biofilm development.
Note: Reproduced by permission from Perfectus Biomed Limited http://perfectusbiomed.com/cbe-meeting-anti-biofilm-technologies/.151
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on tonsils which have been recently inflamed”.74 One study 
showed that 0.6 episode of any type of a sore throat was 
reported in the first year after surgery compared to medical 
intervention,75 and another reported that surgery could lead 
to life-threatening complications. A Swedish cohort study 
reports that among post-tonsillectomy patients 20 years later, 
there was a higher incidence of “chronic, immune-mediated 
 diseases … in the operated group”, with a statistically sig-
nificant relationship between post-tonsillectomy and chronic 
disease, with a  relative risk (RR) at 9.41 and a CI from 1 
(1.13 < RR < 78.14).76 However, another research study 
focusing on adults found that tonsillectomy promotes and 
improves long-term health and quality of life, thus saving 
health resources.77
The decision to operate should therefore be taken with 
care based on an individual patient’s needs and history, plus 
current research evidence.74,76,78,79 In making such decisions, 
secondary care doctors and family medicine practitioners 
need to collaborate because the decision whether a tonsil-
lectomy is necessary is quite difficult and both the general 
practitioner (GP) and the otolaryngologist must contribute 
equally.74 The GP knows about the patient’s frequency, dura-
tion, and severity of tonsillitis, whereas the ear, nose and 
throat specialist will evaluate symptoms relating to nasal and 
Eustachian impediment, and will assess whether symptoms 
are due to tonsillitis or chronic sinusitis.74
Treatments aimed at disrupting 
biofilms
Microbial biofilm formation is responsible for the devel-
opment of acute-to-chronic infection in several diseases 
including cystic fibrosis, periodontitis, infective endocarditis, 
persistent otitis media, chronic rhinosinusitis, chronic ton-
sillitis, prostatitis, chronic osteomyelitis, atopic dermatitis, 
onychomycosis, dental caries, infectious kidney stones, and 
chronic wounds.80–83 Biofilms can also form on any surface, 
living or nonliving, even on clinical devices like pacemakers, 
implants, and catheters, and are very difficult to eradicate, 
which accentuates clinical consequences; for example, 
pseudomonal infections can affect any part of the human 
body. Furthermore, the microorganisms’ adaptive capabil-
ity and genetic changes within the biofilm lead to resistance 
to all known antimicrobial medicines. Pseudomonal infec-
tions in particular become really difficult to be treated and 
can threaten human life.83,84 It is thought that 99% of the 
biosphere’s bacteria live in and that microbial communi-
ties gain an advantage living in this state.85 Consequently, 
microbial biofilms are thought to significantly affect human 
health by increasing morbidity, mortality, and health care 
cost. Biofilms not only add to hospital-acquired infections 
(HAIs) by increasing their chronicity and persistence but also 
colonize in other areas of the environment instigating cor-
rosion, fouling of water pipes, and food and pharmaceutical 
decomposition.14,86–88 Another study reported that microbial 
biofilms can stick onto and infect all medical devices such 
as orthopedic prostheses and intravascular catheters and 
promote up to 60% of HAIs.89
Microorganisms in biofilms are distinctively more resis-
tant to antimicrobial agents and environmental insults and are 
therefore very difficult to eradicate.42,90–94 Biofilms in general 
(and chronic tonsillitis specifically) can therefore lead to 
substantial economic costs for countries and individuals and 
health concerns and are an evolving public health problem in 
both high- and low-resource settings.77,95–100 For this reason, 
multiple research studies have attempted to resolve the issues 
of both biofilms and recurrent tonsillitis.59,61,101–108
The explosion of antibiotic resistance throughout the 
world of many microbial strains has put pressure on the 
research and medical communities to find an alternative 
strategy for the management of biofilm-mediated diseases.61 
“Perhaps new antibiotics are not the only way to combat bio-
film infections if we could make ineffective older antibiotics 
active again.”59 In one study, a 2-amino-imidazole molecule 
was developed which was capable of disrupting biofilms 
through making microorganisms which were previously 
antibiotic-resistant more vulnerable to older antimicrobi-
als.59,62 Immunotherapy (using cyclic dinucleotides) has 
been effective in the management of different cancers, and 
this molecule has also been utilized as a therapeutic strat-
egy for biofilm-related infections. Immunoprophylaxis and 
immunotherapy might therefore provide new tools to combat 
Staphylococcus epidermis biofilm formation.109,110 Recently, 
multiple studies revealed that a 3,5-cyclic diguanylic acid 
(c-di-GMP)-binding protein was found in biofilm communi-
ties.111,112 BdcA (a protein that enhances biofilm dispersal) 
confiscates c-di-GMP and minimizes its local concentration 
and is partly responsible for the reduction and downregulation 
of EPSs of biofilms and for the upregulation of swimming, 
swarming, and planktonic microbes.111,112 This phenomenon 
has been observed in Pseudomonas sp. and Rhizobium meli-
loti biofilm communities.111,112 Multiple groups of scientists 
recently reported that CdrA (an adhesin compound) which 
is produced by biofilms in response to high levels of c-di-
GMP binds with Psl and stabilizes biofilm structure.38,106,113 
Multiple research studies have identified at least three 
extracellular polysaccharides (Alginate, Pel, and Psl) that 
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are important factors for structure maintenance and antibi-
otic resistance of biofilm.114–123 Another study revealed that 
exogenous addition of d-amino acids109 disrupted preformed 
biofilms by disturbing adhesive fiber interactions and was 
also effective in preventing biofilm formation by Staphylo-
coccus aureus and Pseudomonas aeruginosa.124–126 Another 
research study reported that biofilm-disassembly molecule 
is norspermidine which has a similar dispersal mechanism 
to d-amino acids by targeting the exopolysaccharides.125 The 
biofilm-inhibiting properties of norspermidine were detected 
in S. aureus and Escherichia coli pellicle biofilm.125 Current 
research therefore needs to focus on the development of nor-
spermidine, BdcA, d-amino acids, and other polyamines as a 
novel antibiofilm approach, and medical communities should 
no longer depend exclusively on antimicrobials (which are 
increasingly ineffective with many pathogenic microorgan-
isms because of resistance) and surgery to treat infectious 
diseases.104,111,112,124,125
Other studies have identified additional ways of disrupting 
biofilms. Bioactive enzymes such as dispersin or Proteinase K 
studied in orthopedic implants made bacteria more susceptible 
to antibiotics and finally eradicated the biofilm by affecting 
polymers or proteins of the biofilm structure.127 Several cyto-
toxic agents have also been found to successfully eliminate 
biofilms from implant surfaces, with citric acid being reported 
to be the most successful in eradicating biofilms on titanium 
surfaces.128 Multiple research studies have identified that 
electrical current can successfully detach S. aureus and S. 
epidermis biofilms from stainless steel implants.129–131 Another 
study observed that biofilms of S. epidermis on stainless 
steel fasteners were successfully eradicated through pulsed 
electromagnetic fields in combination with gentamicin.132 
A new cluster of research studies have used laser-generated 
shockwaves to effectively break up biofilms.133 The technique 
was performed using a Q-switched, ND:YAG rhythmically 
laser functioning at a “rep rate of 10 Hz with 1500 mJ pulses 
centered at 1064 nm. The laser pulses were used to create 
shockwave pulses in Al coated polycarbonate substrates and 
a resulting peak stress of greater than 50 MPa” was able to 
reduce 55% living microorganisms.134 The laser technique 
offers another way of disrupting biofilms and is useful in the 
management of infected wounds, where standard treatment 
modalities such as topical antimicrobials or the removal of 
dead, damaged, or infected tissue are unsuccessful or injurious. 
One study found that just 4–10 seconds of the laser therapy 
was able to disperse 97.9% of P. aeruginosa from biofilms on 
nitinol stents to single-celled planktonic microorganisms that 
can be more easily treated with antibiotics.135 Another found 
that laser-generated shockwaves therapy quickly disrupts the 
biofilms in infected wounds to eliminate the microorganisms 
and intensify the effectiveness of topical antimicrobials in the 
residual biofilm. Such interventions will promote patients’ 
quality of life by reducing healing times and morbidity, and 
save health care costs.136
N-acetyl-cysteine (NAC) is an antioxidant mediator 
which reduces the variety of microbial bacteria on biofilm 
emergence and evolution,137 inhibits the manufacturing of the 
extracellular polysaccharide matrix,138 and promotes the dis-
ruption of mature biofilms.133 NAC has been found to reduce 
Streptococcus pneumoniae and Haemophilus influenzae 
adhesion to human oropharyngeal epithelial cells in labora-
tory experiments.138 Chronic infections raise prostaglandin 
levels, and NAC effectively reduces these levels and helps 
to disrupt the biofilms.139–142 Correspondingly, aspirin-like 
non-steroidal anti-inflammatory drugs (NSAIDs) decrease 
biofilm production and completely block fungal infections.143 
NAC interacts with the sulfhydryl group of enzymes involved 
in EPS production or excretion, which reduces the activity 
of these molecules or inhibits cysteine utilization.144 NAC, 
therefore, decreases in vitro biofilm formation,145 and other 
research on salicylates shows a similar negative effect on 
the production of biofilm.146 A study which applied both 
found that therapeutic doses of acetylsalicylic acid (ASA) 
and NAC diminish tonsillar mucosal biofilm formation in 
chronic or recurrent tonsillitis.102 Another Iraqi study found 
a strong correlation between the biofilm of Streptococcus 
pyogenes and recurrent tonsillitis and that three types of 
vinegar eradicated streptococcal biofilm remarkably: date 
(100%), apple (95.5%), and grape (90.9%).105 A later study 
also demonstrated the potential of vinegar in eradicating 
tonsillar biofilm.101 In a laboratory experiment, while washing 
and cleaning with a soft brush did not remove the chronic 
tonsillitis biofilm layer on the tonsil surface, using a harder 
brush removed more biofilm.103 Researchers believe that the 
physical removal of biofilm (by brushing or using ultrasound-
activated bubbles) from the tonsil surface in vivo will lead to 
greater effectiveness of topical antimicrobials and decrease 
the need for systemic antimicrobials.103
Conclusion
Recurrent or chronic tonsillitis is currently a global public 
health issue which can severely impair an individual’s quality of 
life.77,147 Microbial biofilms are a major cause of repeated ton-
sillitis in both pediatric and adult cohorts, and more research is 
needed to develop new treatment  strategies.107,148,149 Treatment 
modalities should however be based on careful selection and 
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individual consideration of the potential impact of biofilms on 
cases of recurrent tonsillitis.74 Rather than developing or using 
more potent  antimicrobials, doctors should ensure they are up-
to-date with research and the treatment of biofilms,  including 
the application of topical agents, the physical removal of 
biofilms, and other innovative treatments.
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